

Table S1: Clinical trials currently recruiting PDAC patients for the treatment with at least one immuno-therapy agent.

ClinicalTrials.gov Search Results 11/16/2021

	Title	Status	Study Results	Conditions	Interventions	Locations
1	A Beta-only IL-2 ImmunoTherapY (ABILITY) Study	Recruiting	No Results Available	<ul style="list-style-type: none">•Advanced Solid Tumor•Unresectable Solid Tumor•Melanoma•Renal Cell Carcinoma•Sarcoma•Triple Negative Breast Cancer•Pancreatic Ductal Adenocarcinoma•Non-Small Cell Lung Cancer Squamous•Non-Small Cell Lung Cancer Non-squamous•Colorectal Cancer•and 12 more	<ul style="list-style-type: none">•Drug: MDNA11 Monotherapy•Drug: MDNA11 in combination with checkpoint inhibitor	<ul style="list-style-type: none">•Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia•Scientia Clinical Research, Randwick, New South Wales, Australia•Gallipoli Medical Research Foundation, Greenslopes, Queensland, Australia•ICON Cancer Center, South Brisbane, Queensland, Australia•Cabrini Research, Malvern, Victoria, Australia
2	Study of INCA 0186 in Subjects With Advanced Solid Tumors	Recruiting	No Results Available	<ul style="list-style-type: none">•Advanced Solid Tumors•Squamous Cell Carcinoma of the Head and Neck (SCCHN)•Gastrointestinal (GI) Malignancies	<ul style="list-style-type: none">•Drug: INCA00186•Drug: Retifanlimab•Drug: INCB106385	<ul style="list-style-type: none">•The Angeles Clinic and Research Institute, Los Angeles, California, United States•Carolina Bio-Oncology Institute, PLLc, Huntersville, North Carolina, United States
3	Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer	Recruiting	No Results Available	<ul style="list-style-type: none">•Advanced Pancreatic Ductal Adenocarcinoma•Stage II Pancreatic Cancer AJCC v8•Stage IIA Pancreatic Cancer AJCC v8•Stage IIB Pancreatic Cancer AJCC v8•Stage III Pancreatic Cancer AJCC v8•Stage IV Pancreatic Cancer AJCC v8•Unresectable Pancreatic Ductal Adenocarcinoma	<ul style="list-style-type: none">•Drug: Lenvatinib Mesylate•Biological: Pembrolizumab	<ul style="list-style-type: none">•City of Hope Medical Center, Duarte, California, United States
4	A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors	Recruiting	No Results Available	<ul style="list-style-type: none">•Minimal Residual Disease•KRAS G12D•KRAS G12R•NRAS G12D•NRAS G12R•Pancreatic Ductal Adenocarcinoma•Colorectal Cancer•Non-small Cell Lung Cancer•Ovarian Cancer•Cholangiocarcinoma•Bile Duct Cancer•Gallbladder Carcinoma	<ul style="list-style-type: none">•Drug: ELI-002 2P	<ul style="list-style-type: none">•City of Hope, Duarte, California, United States•University of California Los Angeles, Los Angeles, California, United States•University of Colorado, Aurora, Colorado, United States•University of Iowa, Iowa City, Iowa, United States•Massachusetts General Hospital, Boston, Massachusetts, United States•Henry Ford Cancer Institute, Detroit, Michigan, United States•Washington University School of Medicine, Saint Louis, Missouri, United States•Northwell Health, Lake Success, New York, United States•Memorial Sloan Kettering Cancer Center, New York, New York, United States•Tennessee Oncology - Centennial Clinic, Nashville, Tennessee, United States•The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

	Title	Status	Study Results	Conditions	Interventions	Locations
5	Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer	Recruiting	No Results Available	•Pancreatic Ductal Adenocarcinoma	•Drug: Gemcitabine •Drug: Nab paclitaxel •Drug: NLM-001 •Drug: Zalifrelimab	•Hospital Universitario Virgen De La Victoria, Málaga, Andalucía, Spain •Hospital Universitario Miguel Servet, Zaragoza, Aragón, Spain •Hospital Universitari Vall d'Hebron, Barcelona, Cataluña, Spain •Hospital Universitario Donostia, San Sebastián, País Vasco, Spain
6	Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.	Recruiting	No Results Available	•Metastatic Pancreatic Cancer	•Drug: Nab-paclitaxel •Drug: Gemcitabine •Drug: Cisplatin •Drug: Irinotecan •Drug: Capecitabine •Drug: Pembrolizumab •Drug: Olaparib	•Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
7	PANFIRE-3 Trial: Assessing Safety and Efficacy of Irreversible Electroporation (IRE) + Nivolumab + CpG for Metastatic Pancreatic Cancer	Recruiting	No Results Available	•Pancreatic Cancer •Metastatic Pancreatic Cancer	•Device: Irreversible Electroporation (IRE) •Drug: Nivolumab •Drug: Toll-Like Receptor 9	•Amsterdam University Medical Centre (location VUmc), Amsterdam, North-Holland, Netherlands
8	Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer	Recruiting	No Results Available	•Metastatic Pancreatic Ductal Adenocarcinoma •Stage IV Pancreatic Cancer AJCC v8	•Biological: Dostarlimab •Drug: Niraparib	•Mayo Clinic in Arizona, Scottsdale, Arizona, United States •Mayo Clinic in Florida, Jacksonville, Florida, United States •Mayo Clinic in Rochester, Rochester, Minnesota, United States
9	Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected MMR-p Colorectal and Pancreatic Cancer	Recruiting	No Results Available	•Colorectal Cancer •Pancreatic Cancer	•Drug: KRAS peptide vaccine •Drug: Nivolumab •Drug: Ipilimumab	•Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
10	Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer	Recruiting	No Results Available	•Borderline Resectable Pancreatic Adenocarcinoma •Resectable Pancreatic Ductal Adenocarcinoma	•Drug: Fluorouracil •Drug: Irinotecan •Drug: Irinotecan Hydrochloride •Drug: Leucovorin •Drug: Leucovorin Calcium •Biological: Nivolumab •Drug: Oxaliplatin •Procedure: Therapeutic Conventional Surgery	•UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
11	Maintenance With OSE2101 Plus FOLFIRI, or FOLFIRI After FOLFIRINOX-based Induction Therapy in Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma	Recruiting	No Results Available	•Pancreatic Ductal Adenocarcinoma •Locally Advanced Cancer •Metastatic Cancer	•Drug: FOLFIRI •Drug: OSE2101	•Clinique de l'Europe, Amiens, France •Hôpital Sud CHU Amiens, Amiens, France •CH Beauvais, Beauvais, France •CHRU Jean Minjoz, Besançon, France •Clinique Tivoli Ducos, Bordeaux, France •CHU Morvan, Brest, France •GHPSO Site de Creil, Creil, France •Hôpital Henri Mondor, Créteil, France •Centre Georges François Leclerc, Dijon, France •CHU Dijon, Dijon, France •and 18 more

	Title	Status	Study Results	Conditions	Interventions	Locations
12	Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.	Recruiting	No Results Available	<ul style="list-style-type: none">•Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)•Pancreatic Ductal Adenocarcinoma	<ul style="list-style-type: none">•Radiation: Stereotactic Body Radiation (SBRT)•Drug: Nivolumab•Drug: CCR2/CCR5 dual antagonist•Drug: GVAX	<ul style="list-style-type: none">•Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
13	Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma	Recruiting	No Results Available	<ul style="list-style-type: none">•Resectable Pancreatic Ductal Adenocarcinoma (PDAC)•Pancreatic Ductal Adenocarcinoma	<ul style="list-style-type: none">•Drug: Pembrolizumab•Drug: Defactinib	<ul style="list-style-type: none">•Samuel Oschin Cancer Center at Cedars-Sinai, Los Angeles, California, United States•Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
14	A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.	Recruiting	No Results Available	<ul style="list-style-type: none">•Non-small Cell Lung Cancer (NSCLC)•Triple Negative Breast Cancer (TNBC)•Pancreatic Ductal Adenocarcinoma (PDAC)•Colorectal Cancer Microsatellite Stable (MSS)•Ovarian Cancer•Renal Cell Carcinoma (RCC)•Metastatic Castration Resistant Prostate Cancer (mCRPC)	<ul style="list-style-type: none">•Other: NZV930•Other: PDR001•Drug: NIR178	<ul style="list-style-type: none">•H Lee Moffitt Cancer Center and Research Institute Inc, Tampa, Florida, United States•University of Texas MD Anderson Cancer Center MD Anderson PSC, Houston, Texas, United States•Novartis Investigative Site, Melbourne, Victoria, Australia•Novartis Investigative Site, Toronto, Ontario, Canada•Novartis Investigative Site, Montreal, Quebec, Canada•Novartis Investigative Site, Chuo ku, Tokyo, Japan•Novartis Investigative Site, Singapore, Singapore•Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain•Novartis Investigative Site, Madrid, Spain•Novartis Investigative Site, Sutton, Surrey, United Kingdom
15	Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors	Recruiting	No Results Available	<ul style="list-style-type: none">•Metastatic Castration-resistant Prostate Cancer•Metastatic Prostate Cancer•Metastatic Pancreatic Ductal Adenocarcinoma•Metastatic Pancreatic Cancer•Metastatic Pancreatic Adenocarcinoma	<ul style="list-style-type: none">•Biological: BPX-601•Drug: Rimiducid	<ul style="list-style-type: none">•Moffitt Cancer Center, Tampa, Florida, United States•Emory Winship Cancer Institute, Atlanta, Georgia, United States•John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, United States•Columbia University Medical Center, New York, New York, United States•Tennessee Oncology, PLLC, Nashville, Tennessee, United States•Baylor Sammons Cancer Center, Dallas, Texas, United States•The University of Texas MD Anderson Cancer Center, Houston, Texas, United States